Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Cleanup crew

    Forty Seven and counting Targets & Mechanisms Cleanup crew In a pair of Nature and Science Translational Medicine studies, Stanford University teams have shown blocking the "don't eat me" cell surface protein CD47 …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: Chasing CD47

    Forty Seven and counting Targets & Mechanisms Chasing CD47 At least six companies are developing compounds to block the anti-phagocytic cell surface protein CD47, either with CD47-targeting antibodies or with …

    Published on 8/25/2016
  • Forty Seven and counting

    Stanford and Forty Seven Inc. count up new indications for CD47 blockade

    With CD47 gaining status as the go-to target in oncology, a pair of Stanford studies suggest the target could extend to cardiovascular disease, transplant biology and more.

    Published on 8/25/2016
  • Go small or go home

    A portable manufacturing unit for single doses of biologics

    An MIT duo has coupled a small scale bioreactor with cellular engineering to produce single-dose biologics, with applications ranging from process development to the battlefield.

    Published on 8/18/2016
  • Figure: Just a little culture

    Go small or go home Tools & Techniques Just a little culture Massachusetts Institute of Technology (MIT) scientists have coupled a state-of-the-art microbioreactor and a genetically engineered yeast strain to …

    Published on 8/18/2016
  • Table: BioCentury Product Profile

    Go small or go home Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Cell line optimized for continuous, switchable production of multiple proteins Concept …

    Published on 8/18/2016
  • SHP-2 sets sail

    How NIBR made the first drug-like SHP-2 inhibitor

    After an industry-wide effort of nearly 20 years, an NIBR team may have cracked the problem of how to drug protein tyrosine phosphatases.

    Published on 8/11/2016
  • Figure: Equilibrating SHP-2

    SHP-2 sets sail Product R&D Equilibrating SHP-2 Researchers at Novartis AG's Novartis Institutes for BioMedical Research (NIBR) have shown that the protein tyrosine phosphatase SHP-2 - a promising cancer target - …

    Published on 8/11/2016
  • Figure: Shipping lines

    SHP-2 sets sail Product R&D Shipping lines Researchers at the Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG (NYSE:NVS; SIX:NOVN), have developed the first selective inhibitor …

    Published on 8/11/2016
  • Table: BioCentury Product Profile

    SHP-2 sets sail Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Allosteric SHP-2 inhibitor that arrests the enzyme in its inactive form Concept Blocks cancer growth …

    Published on 8/11/2016
  • Cereblon ambition

    A structural motif could help Celgene find new targets to send to the proteasome

    Celgene has identified a structural motif at the heart of thalidomide's MOA, and is looking for more proteins with the feature that could pave a path to new drugs.

    Published on 8/4/2016
  • Figure: Good riddance to new rubbish

    Cereblon ambition Targets & Mechanisms Good riddance to new rubbish Celgene Corp. (NASDAQ:CELG) hopes to extend the degradation-based mechanism of action of thalidomide and its analogs, known as imids, to new …

    Published on 8/4/2016
  • Table: BioCentury Product Profile

    Cereblon ambition Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A platform to find substrates for degradation induced by thalidomide analogs (imids) Concept…

    Published on 8/4/2016
  • Figure: Natural death

    Innate harmony Tools & Techniques Natural death NK cell activity is dictated by activating and inhibitory receptors on the cell surface that work together to distinguish tumor cells from healthy cells. NK cell …

    Published on 7/28/2016
  • Table: Natural killer cell therapeutics

    Innate harmony Tools & Techniques Natural killer cell therapeutics Select natural killer (NK) cell therapies and NK cell-directed antibodies in clinical and preclinical development for cancer. There are two primary…

    Published on 7/28/2016
  • Innate harmony

    Why NK cells are the next big thing in immuno-oncology

    NK cells are becoming the new shiny tool in immuno-oncology, filling out company pipelines for their potential as alternatives or partners for CAR T cells.

    Published on 7/28/2016
  • Figure: Membership privileges

    Brexit of brains Strategy Membership privileges Accessibility of EU research funds through Horizon 2020 depends on a country's relationship to the EU. For Member States, it is an integral part of the EU membership …

    Published on 7/21/2016
  • Figure: Shepherd's pie

    Brexit of brains Strategy Shepherd's pie A breakdown of the EU's sources of funding for research, development and innovation, including the amount received by the U.K. during the Seventh Framework Programme (FP7) …

    Published on 7/21/2016
  • Brexit of brains

    Research brain drain dominates post-Brexit fears in U.K.

    Although the U.K.'s life sciences sector anticipates Brexit will hit academia worse than industry, a research brain drain could have repercussions for the whole ecosystem.

    Published on 7/21/2016
  • Figure: Six is better than one

    Apogenix's hex on TNF Product R&D Six is better than one Apogenix AG has developed a platform for designing fusion protein agonists of TNF family receptors that stimulate a high level of receptor signaling by …

    Published on 7/14/2016
  • Table: BioCentury Product Profile

    Apogenix's hex on TNF Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Fusion protein agonists of TNF superfamily receptors designed using the Hexavalent TNF Superfamily…

    Published on 7/14/2016
  • Apogenix's hex on TNF

    How Apogenix is using fusion proteins to tackle immuno-oncology targets

    Apogenix is designing hexavalent TNF receptor ligands to compete with agonist mAbs in the clinic based on better potency from a more natural mode of receptor activation.

    Published on 7/14/2016
  • Figure: Triggering AD

    AChE revisited Targets & Mechanisms Triggering AD Neuro-Bio Ltd. has identified a peptide derived from AChE that is overexpressed in the brain centers that degenerate first in Alzheimer's disease (AD), and has …

    Published on 6/30/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993